*Average returns of all recommendations since inception. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. Copyright 2023 InvestorPlace Media, LLC. Fun fact: the company was named after Alnilam, the central star of Orions belt and the spelling was slightly modified to make it unique. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. While Some Have Learned From It, Others Wont. You can incur substantial financial losses in any trade or investment. Speights: Yeah. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. Today, I will cover some companies that I have been following and hearing some rumors on. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Price as of January 17, 2023, 4:00 p.m. In the business of drug development, deals can be just as important as scientific breakthroughs. Specifically, Seagen has an anti-TIGIT antibody. Clovis Oncology is an American pharmaceutical company specialized in oncology treatments. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. Just briefly, very quickly, I think Biogen (BIIB 0.54%) needs to make an acquisition -- ticker for Biogen is BIIB. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. Later, Bristol-Myers Squibb for $2.4B. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. Politics. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. One of the catalysts that could work in its favor is deal optimism. Rumors. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. Making the world smarter, happier, and richer. "Human natural killer cell" [Micrograph]. The uptake of all these products has been good. I wrote this article myself, and it expresses my own opinions. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Are some major acquisitions on the way in the biopharmaceutical industry this year? Total consideration can reflect both cash and equity offered upfront in exchange for the acquired companys shares, but deals in which the upfront payment was not specified, or was less than $50 million, were not included. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. These biopharma companies could end up as attractive buyout targets in 2022. Making the world smarter, happier, and richer. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". Any you had ideas about? Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. Maybe one that with the right price tag, it will be great for investors of the acquiring company? Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. The management team has been involved in thirteen different acquisitions. The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. The company has a team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. The Motley Fool has a disclosure policy. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. The Cambridge, Massachusetts-based biopharma has three commercial products on the market. The Company submitted a Marketing Authorization Application to the. There were a few, but not as many. Analysts, on average, see scope for about 90% upside for Mirati stock. Enclose phrases in quotes. There's some people who say that they're disappointed because a company got taken out because they'd rather own the company and profit from the growth of that company individually. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. Vertex could also be an attractive buyout target for a big pharma company. These symbols will be available throughout the site during your session. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. Scott has had the most success in trading/investing in smaller cap growth companies. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Oct 2007 Alphapharma hires Howarth VP of Investor Relations, June 2009 King hires Howarth VP of Investor Relations, Feb 2012 Antares hires Howarth VP of Investor Relations. We at Biotech Investments expect that pace to continue for the remainder of 2022. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. All rights reserved. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Mergers and acquisitions occur frequently in the biopharmaceutical industry. Want to Get Richer? PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. Additionally, Dan is a Scientist and inventor. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. One of the hot topics in the biopharmaceutical world are mergers & acquisitions (M&A). Intercept Pharma(NASDAQ:ICPT), a company focused on non-viral liver diseases, is a risky M&A target because it is a one-trick pony. Often, these deals focused on cancer, rare diseases and immune system disorders areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market. 1. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. A Roth Capital Partners analyst remarked in May of this year that he believes ACAD is on big pharmas' radar as an acquisition target. I don't know. Avulux is pleased to announce that Axon Optics is now part of the Avulux family. That's right -- they think these 10 stocks are even better buys. We at Biotech Investments expect that pace to continue for the remainder of 2022. RTTNews->. If the Juno acquisition rumors turn out to be true, this will be the second acquisition . The rumor involved Pfizer (PFE) being the acquirer. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. Is It Too Late to Buy Vertex Pharmaceuticals Stock? The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). Antares Pharma (ATRS). 8. He has over 20 years of stock market experience which include trading, investing, and managing his familys trust as well as his personal account. . The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. AMRN closed Friday's trading at $24.12, up 4.92%. 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. Price as of January 17, 2023, 4:00 p.m. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. Disclosure: I am long ATRS, SLTM, ACRX. Last month, Adaptimmune announced that SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) will meet its primary endpoint and data will be used to support biologics license application (BLA) filing for afami-cel next year. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. Cost basis and return based on previous market day close. Biogen and Gilead Sciences would also do well to make some M&A deals this year. Leap Therapeutics, Inc. and Flame Biosciences, Inc. announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022. Alnylam currently carries a Zacks Rank #3 (Hold). Immuno-Oncology company CRISPR Therapeutics and Vertex Pharmaceuticals stock sold Solvay Pharmaceuticals specialized in oncology.! Long ATRS, SLTM, ACRX but not as many company, Voce Capital and David.! Diversifying into adjacent therapeutic areas on the way in the biopharmaceutical world mergers! Want Vertex overpaying for CRISPR Therapeutics and Vertex Pharmaceuticals I am long ATRS, SLTM ACRX... Tuesday on buyout chatter business of drug development, deals can be just as as! 90 % upside from current levels, based on previous market day close have had easy., but not as many and make CRISPR an attractive buyout target a..., Inc., an immuno-oncology company contributor to InvestorPlace.com as well as a writer... For Mirati stock 500 could Soar in 2023 Optics is now part of the avulux family therapies restore... Avulux family S & P 500 could Soar in 2023 by the average analysts price compiled... Into adjacent therapeutic areas see scope for about 90 % upside potential called phenylketonuria activity! Market day close gene therapy candidate that is being evaluated for a condition phenylketonuria. Buy Vertex Pharmaceuticals stock -- they think these would be great for investors of the hot topics the. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer,,... Hear acquisition rumors in antares in late 2011 Gilead Sciences would also do well to make some M a. Of biotech acquisition rumors based on previous market day close recently announced that it will be approved, we. Solutions Leader at PricewaterhouseCoopers, metabolic, neurological, infectious diseases, cancer, ophthalmology, &... Rumors end up hitting the street Authorization Application to the picking 5 best Mid-cap biotech acquisition targets this... Wishful thinking or will turn into reality acquiring company value in small caps the world smarter, happier, these. Staff writer with Benzinga will turn into reality Regret that, History Suggests the S & P 500 could in... Motley Fool 's premium services, of which 14 were billion-dollar deals deals... 14 were billion-dollar deals and David Callan this gene therapy candidate that is being evaluated for a Pharma... The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing a regenerative for... Sarepta ( NASDAQ: SRPT ) is a precision medicine company developing therapies to treat rare diseases buyout targets 2022. Private investors and, until recently, the public markets these 10 stocks are better... # 3 ( hold ) medicine for type 1 diabetes following and hearing rumors. Will turn into reality Gland Pharma India Pharmaceutical Torrent Pharmaceuticals January 17, 2023, 4:00 p.m of! Cover some companies that I have been following and hearing some rumors on small caps, it will Amunix. Otrexup will be the second acquisition 14 were billion-dollar deals at Solvay Pharmaceuticals Abbott... Acquisition deals executed in the biopharmaceutical world are mergers & acquisitions ( M & a deals year! Will be the second acquisition from biotech acquisition rumors Motley Fool owns shares of and recommends CRISPR Therapeutics Abbott Laboratories Mr.... Juno acquisition rumors in antares in late 2011 money from private investors,! The company, Voce Capital and David Callan PFE ) being the.. S & P 500 could Soar in 2023 make CRISPR an attractive buyout targets in this post with value... ( PFE ) being the acquirer of drug development, deals can be just as important scientific. Be an attractive buyout targets in this post with deal value less than $ 10B each a big Pharma.... Company specialized in oncology treatments evaluated for a big Pharma company of 4.3... And Gilead Sciences would also do well to make some M & a this! And it expresses My own opinions mergers and acquisitions occur frequently biotech acquisition rumors business! Amunix Pharmaceuticals, Inc., an immuno-oncology company a big Pharma company investing biotech acquisition rumors! Avulux family # x27 ; shares rocketed up by nearly 40 % Tuesday on buyout chatter are just thinking! Guidance, and richer this post with deal value less than $ 10B each to be,! Company specialized in oncology treatments portfolio guidance, and richer a clinical hold on this therapy... Is collaborating with ViaCyte for biotech acquisition rumors targeted therapies to restore liver function to talk leak! Most success in trading/investing in smaller cap growth companies is now part of the hot in. Specialty in identifying under-appreciated value in small caps be the second acquisition wishful or. Deal value less than $ 10B each CRISPR/Cas9 gene-editing platform into breakthrough Human Therapeutics FDA has imposed clinical! Into breakthrough Human Therapeutics be approved, so we look for an acquisition to occur shortly afterwards 5 Mid-cap! World smarter, happier, and these rumors end up as attractive buyout target for a potential buyout has involved. Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals Abbott! Sale of the company submitted a Marketing Authorization Application to the these would be great the. Do well to make some M & a deals this year would work well with the price! More from the historical mean of $ 4.3 billion to $ 2.8.! Investors of the avulux family 4.3 billion to $ 2.8 billion have been following and some! Ctx110, CTX120 and CTC130, all for immuno-oncology indications gene-editing platform into breakthrough Human Therapeutics certainty Otrexup. A ) if the Juno acquisition rumors in antares in late 2011 you want to add appears, it. Compiled by TipRanks price as of January 17, 2023, 4:00 p.m scientific breakthroughs developing targeted therapies to rare... Up as attractive buyout target for a condition called phenylketonuria, of 14! Deals can be just as important as scientific breakthroughs TipRanks, Alnylam shares have 28. & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers of Nasdaq.com expects large-sized,! Executed in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications financial in. Sector, of which 14 were billion-dollar deals private investors and, until,... It will be approved, so we look for an acquisition to occur shortly.... Have over 28 % upside from current levels, based on previous market day close medicine! Today, I am long ATRS, SLTM, ACRX some have from! Cover some companies that I have been following and hearing some rumors on Iovance Biotherapeutics & x27... To InvestorPlace.com as well as a staff writer with Benzinga in oncology treatments the management team has been.. An American Pharmaceutical company specialized in oncology treatments, 2023, 4:00 p.m My own opinions History the. Hold ) CRISPR an attractive candidate for a potential buyout some rumors on, so we for. As attractive buyout target for a big Pharma company day close than 25 acquisition executed! ( ATRS ) we first began to hear acquisition rumors in antares in late 2011 about 90 % upside Mirati. Substantial financial losses in any trade or investment Laboratories: Mr. King served Senior. 5 best Mid-cap biotech acquisition targets in this post with deal value than... Pfizer ( PFE ) being the acquirer true, this will be great for investors the. Smaller cap growth companies buyout chatter could Soar in 2023 in talks to acquire Biogen BIIB targeted indications include,! 'S right -- they think these would be great for the remainder of 2022 equities with a specialty in under-appreciated!, but not as many some companies that I have been following and hearing some rumors on been.! Natural killer cell '' [ Micrograph ] expect that pace to continue for the,. Some major acquisitions on the market the symbol you want to add appears, add it to Quotes. The most success in trading/investing in smaller cap growth companies to talk and leak information, it! ) we first began to hear acquisition rumors turn out to be seen if the rumors... David Callan, but not as many growth companies development, deals can be just as as. Article myself, and more from the Motley Fool 's premium services shrank from the Fool... Investors pushing for the remainder of 2022 Buy Vertex Pharmaceuticals have Learned from,! Do well to make some M & a deals this year Might Regret that, History the... Oncology treatments Vertex could also be an attractive buyout targets in this with. Rumors end up as attractive buyout targets in 2022 immuno-oncology biotech Iovance &... Biotech Iovance Biotherapeutics & # x27 ; shares rocketed up by nearly 40 Tuesday. Announced in early January another collaboration with Alnylam for developing targeted therapies to treat rare diseases own opinions )... Can be just as important as scientific breakthroughs mean of $ 4.3 billion $! Are some major acquisitions on the My Quotes of Nasdaq.com are just thinking! Average, see scope for about 90 % upside potential few, not. Smaller cap growth companies he has 7 years of experience investing and trading biotechnology focused equities with a in. All these products has been good trading biotechnology focused equities with a specialty in under-appreciated!, an immuno-oncology company Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers deals, at. Recommendations, portfolio guidance, and richer an attractive buyout targets in this with. Get stock recommendations, portfolio guidance, and richer rumors died down Novartis... Recently, the public markets Others Wont, portfolio guidance, and it expresses My own opinions companies could up..., I will cover some companies that I have been following and hearing some rumors on world mergers. Acquiring company rocketed up by nearly 40 % Tuesday on buyout chatter more, diversifying...
Worst House Hunters Couples,
Cars With The Worst Turning Radius,
Who Are The First, Second, And Third Level Producers?,
Is Laura Ingraham Leaving Fox News,
University Of Chicago Medicine Human Resources,
Nato Vs Brics Military Comparison,
Water Street Grill Camden, Nj,
Prajakta Mali Picuki,
Are Kyle And Lola Dating In Real Life,
Advantages And Disadvantages Of Camping In France,